Our findings suggest that targeting these antioxidant pathways could be a promising way of treating HR-NB
Erastin functions to induce ferroptosis through the inhibition of system xc
You crave energy even after eating
Evaluating Ongoing or Alternative Therapeutic Options For patients at high risk of significant weight regain based on biomarkers, genetic predispositions, or baseline metabolic dysfunction, your provider may recommend ongoing GLP-1 therapy at a lower maintenance dose, periodic dosing, or transition to alternative compounds
Many users also report feeling lighter and more comfortable throughout the day
The compound shows high enzymatic selectivity, preserves lean mass, and engages longevity-related pathways (e.g., SIRT1), but remains a nonFDA-approved research substance that is WADA-banned and should be used under medical guidance